Back to top
more

Cigna Group (CI)

(Delayed Data from NYSE)

$290.36 USD

290.36
2,573,924

-3.40 (-1.16%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $290.48 +0.12 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 4% (234 out of 245)

Industry: Medical - HMOs

Zacks News

Kaibalya Pravo Dey headshot

Healthcare Executives Bullish on 2025: But Why Are Stocks Slipping?

Improving the consumer experience, engagement and trust is emerging as a top strategy for healthcare companies.

Zacks Equity Research

SEM Plunges 48.2% in 6 Months: Should You Buy, Hold or Sell the Stock?

Rising expenses and high leverage are impacting Select Medical's prospects.

Zacks Equity Research

Here's Why Cigna (CI) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Mark Vickery headshot

Top Research Reports for ServiceNow, AMD & Sanofi

Today's Research Daily features new research reports on 16 major stocks, including ServiceNow, Inc. (NOW), Advanced Micro Devices, Inc. (AMD) and Sanofi (SNY), as well as two micro-cap stocks Team, Inc. (TISI) and United-Guardian, Inc. (UG).

Kaibalya Pravo Dey headshot

Elevance Health Stock Plunges 29.6% in Q4: Buy, Hold or Sell?

ELV is reallocating resources to more profitable areas and making prudent acquisitions.

Zacks Equity Research

Cigna (CI) Soars 6.3%: Is Further Upside Left in the Stock?

Cigna (CI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Here's Why Cigna (CI) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Here's Why Retaining Cigna Stock is a Smart Move for Investors Now

CI is well-poised for growth on the back of strong contributions from the Evernorth and Cigna Healthcare units. A strong financial position enables it to undertake business investments.

Zacks Equity Research

Here's Why Cigna (CI) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Cigna Ends Humana Merger Speculation: CI Jumps 7.3% While HUM Slips

CI reaffirms its 2024 outlook, projecting full-year adjusted EPS to be a minimum of $28.40.

Zacks Equity Research

Acadia Healthcare Shares Down 18.7% Despite Q3 Earnings Beat

ACHC's better-than-expected third-quarter earnings benefit from higher patient days and improving volumes. Closing two facilities led the company to reduce its 2024 revenue guidance.

Zacks Equity Research

Select Medical Up 13.8% Since Q3 Earnings Top on Patient Day Growth

SEM's strong third-quarter results benefit from improving patient days and admissions in the Rehabilitation Hospital segment. Elevated expenses partially offset the positives.

Zacks Equity Research

Here's Why Cigna (CI) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Tenet Q3 Earnings Beat on Strong Ambulatory Unit, '24 EPS View Raised

THC's Q3 results benefit from higher same-hospital admissions and Medicaid supplemental revenue gains. Cost-cutting measures help offset challenges from hospital divestitures.

Zacks Equity Research

Company News for Nov 1, 2024

Companies In The Article Are: MET,CI, BMY, MO

Zacks Equity Research

Cigna (CI) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for Cigna (CI) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Cigna Q3 Earnings Beat on Client Wins & Specialty Business Strength

CI's strong third-quarter results benefit from a strong Evernorth Health Services segment. Higher expenses partially offset the positives.

Zacks Equity Research

Cigna (CI) Surpasses Q3 Earnings and Revenue Estimates

Cigna (CI) delivered earnings and revenue surprises of 4.02% and 6.46%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will a Strong Evernorth Unit Benefit Cigna in Q3 Earnings?

CI's Q3 results are likely to be aided by strength in the specialty pharmacy business, partly offset by elevated medical costs resulting from higher utilization trends.

Zacks Equity Research

Countdown to Cigna (CI) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Get a deeper insight into the potential performance of Cigna (CI) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Equity Research

Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana and Molina Healthcare

UnitedHealth, The Cigna, Humana and Molina Healthcare are part of the Zacks Industry Outlook article.

Mark Vickery headshot

Top Stock Reports for AbbVie, ADP & Analog Devices

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Automatic Data Processing, Inc. (ADP) and Analog Devices, Inc. (ADI), as well as two micro-cap stocks Taylor Devices, Inc. (TAYD) and Village Super Market, Inc. (VLGEA).

Zacks Equity Research

Elevance Health's Q3 Earnings Miss Due to Medicaid Redeterminations

ELV's third-quarter earnings are hurt by declining membership in Medicaid and Medicare, partially offset by improved product revenues.

Zacks Equity Research

4 HMO Stocks to Watch Despite Continued Industry Headwinds

The Medical-HMO industry is aided by rising health insurance premiums and strategic M&A moves, but faces margin pressure from high-tech costs and staffing shortages. UNH, CI, HUM and MOH are likely to navigate industry storms.